Cleveland BioLabs (CBLI) versus Dyadic International (DYAI) Financial Analysis

Cleveland BioLabs (NASDAQ:CBLI) and Dyadic International (OTCMKTS:DYAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Cleveland BioLabs and Dyadic International’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cleveland BioLabs $1.95 million 10.84 -$9.70 million N/A N/A
Dyadic International $760,000.00 66.07 -$2.14 million ($0.17) -11.06

Dyadic International has lower revenue, but higher earnings than Cleveland BioLabs.

Insider & Institutional Ownership

4.5% of Cleveland BioLabs shares are owned by institutional investors. Comparatively, 0.0% of Dyadic International shares are owned by institutional investors. 2.0% of Cleveland BioLabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Dyadic International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs -245.29% -75.80% -56.63%
Dyadic International -841.68% N/A N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Cleveland BioLabs and Dyadic International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cleveland BioLabs 0 0 0 0 N/A
Dyadic International 0 0 0 0 N/A

Volatility & Risk

Cleveland BioLabs has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Summary

Dyadic International beats Cleveland BioLabs on 5 of the 9 factors compared between the two stocks.

Cleveland BioLabs Company Profile

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Dyadic International Company Profile

Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications; and the Sanofi-Aventis Deutschland GmbH to explore the potential of its C1 technology to produce various types of biologic vaccines and drugs of interest for human health indications. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Receive News & Ratings for Cleveland BioLabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit